Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 04 2020 - 7:22AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
December 4, 2020
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk files for US FDA regulatory approval of once- weekly semaglutide
2.4 mg for weight management
Bagsværd,
Denmark, 4 December 2020 – Novo Nordisk today announced the submission of a new drug application (NDA) to the
US Food and Drug Administration (FDA) for subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue
for chronic weight management. A priority review voucher has been applied to the NDA, leading to an anticipated review time of
six months from the submission date, according to standard FDA review timelines.
The potential indication
is for the treatment of adults with obesity (BMI ≥ 30 kg/m2)
or overweight (BMI ≥ 27 kg/m2)
with at least one weight-related comorbidity, as an adjunct to reduced-calorie diet and increased physical activity.
The submission is based on the results from
the STEP phase 3a clinical trial programme, which included more than 4,500 adults with obesity or overweight. Across the STEP programme,
people with obesity treated with once-weekly semaglutide 2.4 mg achieved a statistically significant and superior reduction in
body weight compared to placebo. Across STEP 1, 3 and 4 a weight loss of 15-18% was reported for people treated with semaglutide
2.4 mg. Furthermore, once-weekly semaglutide 2.4 mg appeared to have a safe and well-tolerated profile. The most common side effects
were gastrointestinal and were transient, and mild or moderate in severity.
“Obesity is associated with a wide range
of serious complications, yet many healthcare providers still do not have sufficient medical options available to help people with
this chronic disease ,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk.
"We are excited about the regulatory filing of semaglutide 2.4 mg in the US and we believe once-weekly semaglutide 2.4 mg
has the potential to transform the medical management of obesity."
Page 2 of 3
About obesity and subcutaneous semaglutide 2.4 mg
for weight management
Obesity is a chronic disease that requires long-term
management. It is associated with many serious health consequences and decreased life expectancy. Obesity-related complications
are numerous and include type 2 diabetes, heart disease, obstructive sleep apnoea, non-alcoholic fatty liver disease and cancer.
Once-weekly subcutaneous semaglutide 2.4 mg
is being investigated by Novo Nordisk as a potential treatment for obesity. Semaglutide is an analogue of the human glucagon-like
peptide-1 (GLP-1) hormone. It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people
eat less and reduce their calorie intake.
About the STEP clinical programme
STEP (Semaglutide Treatment Effect in People
with obesity) is a phase 3 clinical development programme with once-weekly subcutaneous semaglutide 2.4 mg in obesity. The global
phase 3a programme consists of four trials and has enrolled approximately 4,500 adults with overweight or obesity.
STEP
1 – a 68-week safety and efficacy trial of subcutaneous semaglutide 2.4 mg versus placebo in 1,961 adults with obesity or
overweight. For more information, please read the company announcement here (https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=280)
STEP
2 – a 68-week safety and efficacy trial of subcutaneous semaglutide 2.4 mg versus placebo and once-weekly subcutaneous semaglutide
1.0 mg in 1,210 adults with type 2 diabetes and either obesity or overweight. For more information, please read the company announcement
here (https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=278)
STEP
3 – a 68-week safety and efficacy trial of subcutaneous semaglutide 2.4 mg versus placebo in combination with intensive
behavioural treatment in 611 adults with obesity or overweight. For more information, please read the company announcement
here (https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=278)
STEP
4 – a 68-week safety and efficacy trial of subcutaneous semaglutide 2.4 mg versus placebo in 803 adults with obesity or
overweight who have reached the target dose of 2.4 mg after a 20- week run-in. For more information, please read the company announcement
here (https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=286)
Page 3 of 3
About Novo Nordisk
Novo
Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to
defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering
scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs
about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq
Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook,
Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Mette Kruse Danielsen
|
+45 3079 3883
|
mkd@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
Mark Joseph Root
|
+45 3079 4211
|
mjhr@novonordisk.com
|
Kristoffer Due Berg (US)
|
+1 609 235 2989
|
krdb@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 74 / 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: December 4, 2020
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024